Key Factors
Shares of Praxis Precision Medicines (NASDAQ: PRAX) leaped on Monday after the clinical-stage biopharmaceutical firm obtained a Breakthrough Remedy Designation (BTD) for its experimental tremor therapy.
By the shut of buying and selling, Praxis’ inventory worth was up greater than 13%.
The place to take a position $1,000 proper now? Our analyst workforce simply revealed what they imagine are the 10 finest shares to purchase proper now. Proceed »
Picture supply: Getty Pictures.
A promising improvement
Praxis makes a speciality of utilizing genetic insights to find new therapies for neurological issues. The biotech’s efforts obtained a lift in the present day when the U.S. Meals and Drug Administration (FDA) granted a BTD for Praxis’ ulixacaltamide therapy for sufferers with important tremor.
The designation was granted based mostly on the encouraging outcomes from two current part 3 research. The BTD, which is meant to speed up the event of medicine that would considerably enhance the therapy of significant medical situations, ought to assist to hasten a regulatory overview of ulixacaltamide.
Praxis, in flip, plans to submit a New Drug Software for ulixacaltamide in early 2026.
“We lately accomplished a collection of constructive interactions with the FDA, that, along with this BTD, are enabling us to advance this promising therapy quicker to sufferers,” Praxis CEO Marcio Souza stated in a press launch.
A big unmet want
Roughly 7 million individuals are stricken with important tremor within the U.S. alone. The motion dysfunction usually results in involuntary arm actions that may disrupt sufferers’ lives. Present therapy choices aren’t very efficient and are sometimes poorly tolerated.
“The granting of the Breakthrough Remedy Designation for ulixacaltamide … additional underscores its potential to deal with the substantial unmet want in sufferers with ET,” Souza stated.
Must you purchase inventory in Praxis Precision Medicines proper now?
Before you purchase inventory in Praxis Precision Medicines, take into account this:
The Motley Idiot Inventory Advisor analyst workforce simply recognized what they imagine are the 10 finest shares for buyers to purchase now… and Praxis Precision Medicines wasn’t one in every of them. The ten shares that made the minimize may produce monster returns within the coming years.
Take into account when Netflix made this listing on December 17, 2004… in case you invested $1,000 on the time of our advice, you’d have $509,470!* Or when Nvidia made this listing on April 15, 2005… in case you invested $1,000 on the time of our advice, you’d have $1,167,988!*
Now, it’s price noting Inventory Advisor’s complete common return is 991% — a market-crushing outperformance in comparison with 196% for the S&P 500. Do not miss the newest prime 10 listing, accessible with Inventory Advisor, and be a part of an investing neighborhood constructed by particular person buyers for particular person buyers.
See the ten shares »
*Inventory Advisor returns as of December 29, 2025.
Joe Tenebruso has no place in any of the shares talked about. The Motley Idiot has no place in any of the shares talked about. The Motley Idiot has a disclosure coverage.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
